loading page

Is Baloxavir Marboxil the Answer to Treating Childhood Influenza?
  • +2
  • Omer Shaikh ,
  • Sharmeen Fatima,
  • Wardah Navaid,
  • Gulrukh Shaikh,
  • Abdulqadir Nashwan
Omer Shaikh
Ziauddin University Faculty of Medicine

Corresponding Author:[email protected]

Author Profile
Sharmeen Fatima
Dow University of Health Sciences
Author Profile
Wardah Navaid
Dow University of Health Sciences
Author Profile
Gulrukh Shaikh
Liaquat National Hospital and Medical College
Author Profile
Abdulqadir Nashwan
Hamad Medical Corporation
Author Profile


Influenza A and B are the most common causes of respiratory tract-restricted acute viral disease. Each year, it is estimated that around 16% of children aged 5 to 17 are hospitalized. Baloxavir Marboxil has the potential to be an innovative alternative to the existing standard of therapy for these individuals.